Medical Bulletin 22/April/2026

Here are the top medical news for today:

Researchers Achieve Communication Between Artificial Neurons and Living Brain Tissue

What if machines didn’t just mimic the brain—but could actually talk to it?

Engineers at Northwestern University have developed printed artificial neurons that can directly communicate with real brain cells, marking a major step forward in brain-inspired technology. Unlike earlier attempts that only simulated neural activity, these flexible, low-cost devices generate electrical signals that closely match those of living neurons—and can trigger responses in actual brain tissue.

The study was published in the journal Nature Nanotechnology.

In laboratory experiments, the artificial neurons were tested on slices of the mouse brain and successfully activated real neurons. This breakthrough demonstrates a new level of compatibility between electronics and biology, opening the door to advanced brain-machine interfaces and neuroprosthetics. In the future, such systems could help restore lost functions like movement, vision, or hearing by seamlessly connecting devices to the nervous system.

The innovation also has major implications for artificial intelligence. Today’s AI systems rely on massive data processing and consume enormous amounts of energy. In contrast, the human brain performs complex tasks using far less power. By mimicking how neurons naturally communicate, this new technology could lead to ultra-efficient computing systems that dramatically reduce energy use.

At the core of the invention are printable electronic materials, including graphene and molybdenum disulfide, layered onto flexible surfaces using advanced printing techniques. These materials allow the artificial neurons to produce a wide range of brain-like signals—from single spikes to complex firing patterns—without requiring large networks of components.

By bridging the gap between machines and living neurons, this research doesn’t just improve technology—it redefines how closely electronics can integrate with the human body and brain.

REFERENCE: Shreyash S. Hadke, Carol N. Klingler, Spencer T. Brown, Meghana Holla, Xudong Zhuang, Linda Li, M. Iqbal Bakti Utama, Santiago Diaz-Arauzo, Anurag Chapagain, Siyang Li, Jung Hun Lee, Indira M. Raman, Vinod K. Sangwan, Mark C. Hersam. Printed MoS2 memristive nanosheet networks for spiking neurons with multi-order complexity. Nature Nanotechnology, 2026; DOI: 10.1038/s41565-026-02149-6

New Study Links Daily Orange Consumption to Lipid Changes in Fatty Liver Disease

Can something as simple as an orange quietly nudge your liver health in the right direction?

A recent study published in Nutrients explored whether eating “Navelina” oranges daily could improve fat metabolism in people with metabolic dysfunction-associated steatotic liver disease. This condition, closely linked to obesity and Type 2 diabetes, is driven by disruptions in how the body processes fats, increasing the risk of inflammation and long-term liver damage.

In the study, 60 adults with MASLD were divided into two groups. One group consumed 400 grams of oranges daily for four weeks, while the other avoided them. Researchers then analyzed blood samples to track changes in lipid profiles—essentially how fats circulate and behave in the body.

The results were subtle but interesting. While there were no statistically significant changes, participants who ate oranges showed a consistent trend toward improvement. Levels of “bad” cholesterol (LDL) and total cholesterol decreased slightly, while “good” cholesterol (HDL) increased. There were also small shifts in fatty acids, including a reduced ratio of pro-inflammatory compounds, hinting at a move toward a healthier, less inflammatory profile.

These effects may be linked to the natural compounds found in oranges, particularly polyphenols and fiber, which are known to influence fat metabolism and inflammation. However, researchers caution that the findings are preliminary. The study was short—just four weeks—and involved a relatively small group, meaning stronger conclusions cannot yet be drawn.

Still, the results add to growing evidence that diet plays a powerful role in managing metabolic diseases.

While oranges alone are not a treatment, they could become part of a broader dietary strategy for supporting liver health. Larger and longer-term studies will be needed to confirm whether this citrus habit can deliver meaningful clinical benefits.

REFERENCE: Nunzio, V. D., Pinto, G., Guido, D., Caruso, E. A., Cofano, M., Saponara, I., Centonze, M., Refolo, M. G., & Notarnicola, M. (2026). Effect of 4-Week Consumption of “Navelina” Oranges on Serum Lipid Profile in Patients with MASLD: Evidence from a Randomized Clinical Trial. Nutrients. 18(8). DOI: https://doi.org/10.3390/nu18081254. https://www.mdpi.com/2072-6643/18/8/1254

Study Explores Why Heart Disease Risk Is Difficult to Predict in Type 1 Diabetes

What if your weight looks normal—but your heart risk tells a completely different story?

A new study in Nature Communications suggests that traditional measures like body mass index (BMI) may miss hidden cardiovascular dangers in people with Type 1 diabetes. Researchers analyzed data from nearly 44,000 patients across Europe and found that combining BMI with deeper metabolic markers can significantly improve how doctors predict the risk of cardiovascular disease.

People with Type 1 diabetes already face a higher risk of heart disease, even when their blood sugar appears well controlled. This makes early and accurate risk detection especially important. Instead of relying on BMI alone, the study used a “discordance” model—essentially comparing a person’s weight with what their internal biomarkers, such as cholesterol, blood pressure, and blood sugar, reveal about their health.

The findings were striking. A “hyperglycemic” profile—where blood sugar levels are high regardless of body weight—was far more common in Type 1 diabetes than in the general population. In fact, it appeared in over half of patients studied. This group showed higher levels of HbA1c, a key marker of long-term blood sugar control, and carried a higher cardiovascular risk.

When researchers added these profiles to existing prediction tools like SCORE2, the accuracy of identifying major heart-related events improved in several groups, particularly among men. Even small improvements mattered: the model helped identify more high-risk individuals while reducing unnecessary treatments in others.

The study highlights a crucial shift in thinking—cardiovascular risk isn’t just about weight. For people with Type 1 diabetes, what’s happening inside the body may matter far more. By refining risk prediction, doctors could better target prevention strategies and catch complications earlier, ultimately improving long-term outcomes.

REFERENCE: Pazmino, S., Schmid, S., Blanch, J., et al. (2026). Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis. Nature Communications. DOI: https://doi.org/10.1038/s41467-026-72029-z. https://www.nature.com/articles/s41467-026-72029-z